1332 related articles for article (PubMed ID: 16596770)
1. Pharmacological actions of cannabinoids.
Pertwee RG
Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
[TBL] [Abstract][Full Text] [Related]
2. The pharmacology of cannabinoid receptors and their ligands: an overview.
Pertwee RG
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
[TBL] [Abstract][Full Text] [Related]
3. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
Pertwee RG
Life Sci; 2005 Feb; 76(12):1307-24. PubMed ID: 15670612
[TBL] [Abstract][Full Text] [Related]
4. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.
De Petrocellis L; Di Marzo V
J Neuroimmune Pharmacol; 2010 Mar; 5(1):103-21. PubMed ID: 19847654
[TBL] [Abstract][Full Text] [Related]
5. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids Stimulate the TRP Channel-Dependent Release of Both Serotonin and Dopamine to Modulate Behavior in
Oakes M; Law WJ; Komuniecki R
J Neurosci; 2019 May; 39(21):4142-4152. PubMed ID: 30886012
[No Abstract] [Full Text] [Related]
7. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Romero TR; Resende LC; Guzzo LS; Duarte ID
Anesth Analg; 2013 Feb; 116(2):463-72. PubMed ID: 23302980
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
9. Behavioral effects of cannabinoid agents in animals.
Chaperon F; Thiébot MH
Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling.
Hiley CR; Ford WR
Biol Rev Camb Philos Soc; 2004 Feb; 79(1):187-205. PubMed ID: 15005177
[TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanism and Cannabinoid Pharmacology.
Schurman LD; Lu D; Kendall DA; Howlett AC; Lichtman AH
Handb Exp Pharmacol; 2020; 258():323-353. PubMed ID: 32236882
[TBL] [Abstract][Full Text] [Related]
12. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
13. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
Klegeris A; Bissonnette CJ; McGeer PL
Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol skews biased agonism at cannabinoid CB
Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
[TBL] [Abstract][Full Text] [Related]
16. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of cannabinoid receptor ligands: current status.
Singh J; Budhiraja S
Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid 1 (CB1) receptor--pharmacology, role in pain and recent developments in emerging CB1 agonists.
Talwar R; Potluri VK
CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):536-44. PubMed ID: 21631407
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
[TBL] [Abstract][Full Text] [Related]
20. The cannabinoid system and immune modulation.
Klein TW; Newton C; Larsen K; Lu L; Perkins I; Nong L; Friedman H
J Leukoc Biol; 2003 Oct; 74(4):486-96. PubMed ID: 12960289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
